Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Manidipine 6300. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.70 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.70 |
| ▸ | HTR1A | P08908 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Manidipine 6300 SCHEMBL29801590 | 1.00 | MAPT (0.70) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL247471 | 1.00 | MAPT (0.70) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL247919 | 0.99 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL137617 | 0.99 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL1491200 | 0.99 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL137616 | 0.99 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL6275097 | 0.99 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL28185730 | 0.99 | MAPT (0.69) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL678249 | 0.98 | MAPT (0.68) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL28927600 | 0.98 | ADRA1A (0.70) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8319 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4714447-A1 | DRUG COMBINATIONS OF BCL-XL INHIBITORS FOR TREATMENT OF CANCER | Stichting Amsterdam UMC (NL) | 2026-03-25 | — | — | EP | claimed |
| EP-4691462-A1 | SILYBIN-CONTAINING COMPOSITION | Tianjin Tasly Sants Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-13 | — | — | US | claimed |
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250262203-A1 | METHOD FOR TREATING CALCIFIC HEART VALVE DISEASE(CHVD) | UNION HOSPITAL, TONGJI MEDICAL COLLEGE, HUST (CN) | 2025-08-21 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-0639986-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1995-03-01 | — | — | EP | claimed |
| WO-1994012185-A1 | COMBINATION OF A CALCIUM CHANNEL BLOCKER AND AN ANTIOXYDANT FOR TREATING ISCHEMIC DISEASES | THE UPJOHN COMPANY (US) | 1994-06-09 | — | — | WO | claimed |
| US-5310917-A | Process for the preparation of 4-substituted-1,4-dihydropydrines | MERCK & CO., INC. (US) | 1994-05-10 | — | — | US | claimed |
| WO-1993023082-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| CN-1070907-A | Preparation 4-replaces-1, the novel method of 4-dihydropyridine | MERCK & CO INC (US) | 1993-04-14 | — | — | CN | claimed |
| WO-1993006082-A1 | PROCESS FOR THE PREPARATION OF 4-SUBSTITUTED-1,4-DIHYDROPYRIDINES | MERCK & CO., INC. (US) | 1993-04-01 | — | — | WO | claimed |
| EP-0534520-A2 | Process for the preparation of 4-substituted-1,4-dihydropyridines | MERCK & CO. INC. (US) | 1993-03-31 | — | — | EP | claimed |
| EP-0094159-B1 | DIHYDROPYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-03-14 | — | — | EP | claimed |
| US-4892875-A | HYPOTENSIVE, RENAL VASODILATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-01-09 | — | — | US | claimed |
| EP-0094159-A1 | Dihydropyridine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-11-16 | — | — | EP | claimed |